- Home
- LUNG vs BTMD Comparison
LUNG vs BTMD Comparison
Compare LUNG & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUNG | BTMD |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.2M | 64.4M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LUNG | BTMD |
|---|---|---|
| Price | $1.54 | $1.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $5.38 | $2.25 |
| AVG Volume (30 Days) | ★ 646.1K | 201.1K |
| Earning Date | 06-01-2026 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.64 | ★ 722.22 |
| EPS | N/A | ★ 0.74 |
| Revenue | $90,497,000.00 | ★ $192,219,000.00 |
| Revenue This Year | $6.20 | $4.11 |
| Revenue Next Year | $21.61 | $8.50 |
| P/E Ratio | ★ N/A | $1.84 |
| Revenue Growth | ★ 8.01 | N/A |
| 52 Week Low | $1.31 | $1.36 |
| 52 Week High | $7.97 | $4.75 |
Technical Indicators
Market Signals| Indicator | LUNG | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 44.26 | 17.31 |
| Support Level | $1.44 | N/A |
| Resistance Level | $1.97 | $2.76 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 16.67 | 3.01 |
Price Performance
Historical ComparisonAbout LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.